PWM
LTRN icon

Perigon Wealth Management’s Lantern Pharma LTRN Stock Holding History

Perigon Wealth Management’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-39,387
Closed -$139K – 1087
2025
Q1 		$139K Buy
39,387
+24,787
+170% +$103K ﹤0.01% 997
2024
Q4 		$52.6K Sell
14,600
-14,300
-49% -$49K ﹤0.01% 1039
2024
Q3 		$106K Buy
+28,900
New +$119K ﹤0.01% 968

Other funds holding LTRN

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

Perigon Wealth Management's LTRN Position: Q2 2025 in Review

Perigon Wealth Management sold out of Lantern Pharma (LTRN) in Q2 2025, closing a stake of 39,387 shares — an estimated $139K sold.

Perigon Wealth Management first reported a position in LTRN in Q3 2024 and held it in 3 quarters. The position peaked at $139K in Q1 2025. 35 funds tracked by Wall St. Rank hold LTRN as of Q2 2025.

  • Perigon Wealth Management reported no remaining Lantern Pharma position as of Q2 2025 after selling out during the quarter.
  • Perigon Wealth Management sold 39,387 Lantern Pharma shares in Q2 2025, an estimated $139K.
  • Perigon Wealth Management first reported a position in Lantern Pharma in Q3 2024 and held it in 3 quarters.
  • Perigon Wealth Management's Lantern Pharma position peaked at $139K in Q1 2025.
  • 35 funds tracked by Wall St. Rank held Lantern Pharma as of Q2 2025.

Based on Perigon Wealth Management's 13F filing for Q2 2025, filed 16 Jul 2025.